Сочетание бронхиальной астмы и хронической обструктивной болезни легких


https://doi.org/10.18093/0869-0189-2013-0-4-87-94

Полный текст:


Аннотация

Сочетание бронхиальной астмы и хронической обструктивной болезни легких.


Об авторах

В. В. Архипов
ГБОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России
Россия

д. м. н., профессор кафедры клинической фармакологии и пропедевтики внутренних болезней

119991, Москва, ул. Трубецкая, 8, стр. 2. Тел.: (495) 915-59-89.



В. К. Прозорова
ГБОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России
Россия

к. м. н., доцент кафедры клинической фармакологии и пропедевтики внутренних болезней

119991, Москва, ул. Трубецкая, 8, стр. 2. Тел.: (495) 915-59-89.



Д. Е. Архипова
ГБОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России
Россия

к. м. н., ассистент кафедры клинической фармакологии и пропедевтики внутренних болезней  

119991, Москва, ул. Трубецкая, 8, стр. 2. Тел.: (495) 915-59-89.



Список литературы

1. Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 598–604.

2. Cottini M., Asero R. Asthma phenotypes today. Eur. Ann. Allergy Clin. Immunol. 2013; 45 (1): 17–24.

3. Editorial. Asthma: still more questions than answers. Lancet 2008; 372 (9643): 1009.

4. Miravitlles M., Soler3Cataluna J.J., Calle M. et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch. Bronconeumol. 2012; 48 (7): 247–257.

5. Global strategy for asthma management and prevention. Updated December 2012. http://www.ginasthma.org/documents/4

6. Gallefoss F, Bakke P. Does smoking affect the outcome of patient education and self management in asthmatics? Patient Educ. Couns. 2003; 49: 91–97.

7. van Schayck O.C., Haughney J., Aubier M. et al. Do asthmatic smokers benefit as much as non-smokers on budesonide / formoterol maintenance and reliever therapy? Results of an open label study. Respir. Med. 2012; 106 (2): 189–196.

8. Aubier M., Buhl R., Ekstrom T. et al. Comparison of two twice-daily doses of budesonide / formoterol maintenance and reliever therapy. Eur. Respir. J. 2010; 36: 524–530.

9. Eisner M.D., Yelin E.H., Trupin L., Blanc P.D. Asthma and smoking status in a population-based study of California adults. Publ. Hlth Rep. 2001; 116 (2): 148–157.

10. Pedersen S.E., Bateman E.D., Bousquet J. et al. Determinants of response to fluticasone propionate and salmeterol / fluticasone propionate combination in the Gaining Optimal Asthma controL study. J. Allergy Clin. Immunol. 2007; 120 (5): 1036–1042.

11. Chaudhuri R., Livingston E., McMahon A.D. et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003; 168 (11): 1308–1311.

12. Chalmers G.W., Macleod K.J., Little S.A. et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (3): 226–230.

13. O'Byrne P.M., Lamm C.J., Busse W.W. et al. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. Chest 2009; 136 (6): 1514–1520.

14. Chaudhuri R., Livingston E., McMahon A.D. et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am. J. Respir. Crit. Care Med. 2006; 174 (2): 127–133.

15. Barnes P.J., Adcock I.M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25 (3): 552–563.

16. Higenbottam T., Feyeraband C., Clark T. Cigarette smoking in asthma. Br. J. Dis. Chest 1980; 74: 279–284.

17. Dijkstra A., Vonk J.M., Jongepier H. et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 2006; 61 (2): 105–110.

18. Vestbo J., Edwards L.D., Scanlon P.D. et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365 (13): 1184–1192.

19. Lange P., Scharling H., Ulrik C.S., Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006; 61 (2): 100–104.

20. Kerstjens H.A., Overbeek S.E., Schouten J.P. et al. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur. Respir. J. 1993; 6 (6): 868–876.

21. Chalmers G., MacLeod K., Thomson L. et al. Smoking and airway inflammation in patients with mild asthma. Chest 2001; 120: 1917–1922.

22. Chalmers G.W., Macleod K.J., Little S.A. et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (3): 226–230.

23. Green R.H., Brightling C.E., Woltmann G. et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875–879.

24. Dima E., Rovina N., Gerassimou C. et al. Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 287–296.

25. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med. 2012; 18 (5): 716–725.

26. Федосеев Г.Б., Хлопотова Г.П. Бронхиальная астма. Л.: Медицина; 1988.

27. Barnes P.J., Woolcock A.J. Difficult asthma. Eur. Respir. J. 1998; 12 (5): 1209–1218.

28. Fahy J.V. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc. 2009; 6 (3): 256–259.

29. Lange P., Parner J., Vestbo J. et al. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998; 339: 1194–1200.

30. Sorkness R., Bleecker E., Busse W. et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J. Appl. Physiol. 2008; 104: 394–403.

31. Paganin F., Seneterre E., Chanez P. et al. Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am. J. Respir. Crit. Care Med. 1996; 153: 110–114.

32. Barnes P.J. Inhaled corticosteroids in COPD: a controversy. Respiration 2010; 80 (2): 89–95.

33. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648.

34. Kohansal R., Martinez3Camblor P., Agusti A. et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am. J. Respir. Crit. Care Med. 2009; 180 (1): 3–10.

35. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 332–338.

36. Halpin D., Decramer M., Celli B. et al. Impact of a single chronic obstructive pulmonary disease (COPD) exacerbation on lung function decline: Analysis of UPLIFT. In: European Respiratory Society (ERS). 2012 Annual congress. 2012: Abstract 194OC. Presented September 2, 2012.

37. Vestbo J., Edwards L.D., Scanlon P.D. et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365 (13): 1184–1192.

38. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 2002; 166 (8): 1084–1091.

39. Donohue J.F., Anderson W., Wisniewski M. et al. Demographics and bronchoreversibility of salmeterol and ipratropium in a large population of patients with mild-to-moderate COPD [abstract]. Am. J. Respir. Crit. Care Med.1997; 155: A227.

40. Dorinsky P.M., Reisner C., Ferguson G.T. et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115: 966–971.

41. Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58 (8): 659–664.

42. Watt A.P., Schock B.C., Ennis M. Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr. Drug Targets. Inflamm. Allergy 2005; 4 (4): 415–423.

43. Brightling C.E., Monteiro W., Ward R. et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356 (9240): 1480–1485.

44. Bafadhel M., McKenna S., Terry S. et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebocontrolled trial. Am. J. Respir. Crit. Care Med. 2012; 186 (1): 48–55.

45. Siva R., Green R., Briqthlinq C. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomized controlled trial. Eur. Respir. J. 2007; 29: 906–913.

46. Oraka E., Kim H.J., King M.E., Callahan D.B. Asthma prevalence among US elderly by age groups: age still matters. J. Asthma 2012; 49 (6): 593–599.

47. Sherrill D., Guerra S., Bobadilla A., Barbee R. The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur. Respir. J. 2003; 21 (1): 95–100.

48. Schneider A., Tilemann L., Schermer T. et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement – results of a prospective diagnostic study: FENO < or = 16 ppb better than FENO < or =12 ppb to rule out mild and moderate to severe asthma [added]. Respir. Res. 2009; 10: 15.

49. Cazzola M., Puxeddu E., Bettoncelli G. et al. The prevalence of asthma and COPD in Italy: a practice-based study. Respir. Med. 2011; 105 (3): 386–391.

50. Viegi G., Matteelli G., Angino A. et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004; 126 (4): 1093–1101.

51. Soriano J.B., Davis K.J., Coleman B. et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124 (2): 474–481.

52. Mannino D.M., Gagnon R.C., Petty T.L., Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 2000; 160 (11): 1683–1689.

53. Haahtela T., Tuomisto L.E., Pietinalho A. et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663–670.

54. Kim T.B., Oh Y.M., Chang Y.S. et al. The reality of an intermediate type between asthma and COPD in practice. Respir. Care 2012; 57 (8): 1248–1253.

55. Soler3Cataluna J.J., Cosio B., Izquierdo J.L. et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch. Bronconeumol. 2012; 48 (9): 331–337.

56. Duggal R., Menkes D.B. Evidence-based medicine in practice. Int. J. Clin. Pract. 2011; 65 (6): 639–644.

57. Sethi S., Mahler D.A., Marcus P. et al. Inflammation in COPD: implications for management. Am. J. Med. 2012; 125 (12): 1162–1170.

58. Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29 (6): 1115–1119.

59. Loke Y.K, Kwok C.S., Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur. Respir. J. 2010; 35 (5):1003–1021. doi: 10.1183/09031936.00095909.

60. Stallberg B., Selroos O., Vogelmeier C. et al. Budesonide / formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir. Res. 2009; 10: 11.

61. Malmstrom K., Rodriguez3Gomez G., Guerra J. et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast / Beclomethasone Study Group. Ann. Intern. Med. 1999; 130 (6): 487–495.

62. van den Berge M., ten Hacken N.H., Cohen J. et al. Small airway disease in asthma and COPD: clinical implications. Chest 2011; 139 (2): 412–423.

63. To Y., Kharitonov S., Adcock I. et al. Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline. In: Program and abstracts of the European Respiratory Society 15th Annual congress, September 17–21, 2005. Copenhagen, 2005. Abstr. 215.

64. Dolovich M. New delivery systems and propellants. Can. Respir. J. 1999; 6 (3): 290–295.

65. De Backer W., Devolder A., Poli G. et al. Lung deposition of BDP / formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J. Aerosol Med. Pulm. Drug Deliv. 2010; 23 (3): 137–148.

66. Brusselle G., Peche R., Van den Brande P. et al. Real-life effectiveness of extrafine beclometasone dipropionate / formoterol in adults with persistent asthma according to smoking status. Respir. Med. 2012; 106 (6): 811–819.

67. O'Connor B.J., Collarini S., Poli G. et al. Rapid effects of extrafine beclomethasone dipropionate / formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial. BMC Pulm. Med. 2011; 11: 60.

68. Tzani P., Crisafulli E., Nicolini G. et al. Effects of beclomethasone / formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 503–509.

69. Singh D., Kampschulte J., Wedzicha J.A. et al. A trial of beclomethasone / formoterol in COPD using EXACT-PRO to measure exacerbations. Eur. Respir. J. 2013; 41 (1): 12–17.

70. Spears M., Donnelly I., Jolly L. et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur. Respir. J. 2009; 33: 1010–1017.

71. Novelli F., Malagrino L., Dente F.L., Paggiaro P. Efficacy of anticholinergic drugs in asthma. Expert. Rev. Respir. Med. 2012; 6 (3): 309–319.

72. Kerstjens H.A., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367 (13): 1198–1207.


Дополнительные файлы

Для цитирования: Архипов В.В., Прозорова В.К., Архипова Д.Е. Сочетание бронхиальной астмы и хронической обструктивной болезни легких.  Пульмонология. 2013;(4):87-94. https://doi.org/10.18093/0869-0189-2013-0-4-87-94

For citation: Arkhipov V.V., Prozorova V.K., Arkhipova D.E. Co-morbidity of bronchial asthma and chronic obstructive pulmonary disease. Russian Pulmonology. 2013;(4):87-94. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-4-87-94

Просмотров: 411

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)